In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with non-Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read More
In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with non-Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read More
In a nutshell This study investigated the safety and effectiveness of systemic chemotherapy after radiotherapy for early-stage follicular lymphoma. This study concluded that this combined treatment is more effective than radiotherapy alone for early-stage follicular lymphoma. Some background Radiotherapy can help control local disease in more than 90%...
Read More
In a nutshell This article reviewed the front-line treatment options for elderly (65 years or older) patients with mantle cell lymphoma. Some background For older patients with mantle cell lymphoma, the goals of front-line treatment vary. More intense treatments such as chemotherapy can help achieve remission and improve survival. However, frail...
Read More
In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...
Read MoreIn a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...
Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of mantle cell lymphoma. This study concluded that this regimen improved outcomes in patients with mantle cell lymphoma. Some background The standard treatment for mantle cell lymphoma (MCL)...
Read More
In a nutshell This study investigated the safety and effectiveness of coltuximab ravtansine for relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. The authors concluded that coltuximab ravtansine monotherapy was reasonably effective and well-tolerated in these patients. Some background The most widely used treatment...
Read MoreIn a nutshell This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients. Some...
Read MoreIn a nutshell This study looked at the risk of infection in older patients with indolent non-Hodgkin lymphoma (nHL) treated with bendamustine (Treanda). Researchers concluded that nHL patients treated with bendamustine had increased risk of common bacterial, fungal, and viral infections. Some background Bendamustine is a chemotherapy drug sometimes...
Read MoreIn a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) for patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that ibrutinib is effective and well tolerated in everyday clinical practice. Some background Mantle cell lymphoma (MCL) is a rare but aggressive...
Read More
In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...
Read More
